New York, New York--(Newsfile Corp. - June 24, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Frequency Therapeutics, Inc. (NASDAQ: FREQ) alleging that the Company violated federal securities laws.
Class Period: November 16, 2020 and March 22, 2021
Lead Plaintiff Deadline: August 2, 2021
No obligation or cost to you.
Learn more about your recoverable losses in FREQ:
Frequency Therapeutics, Inc. NEWS - FREQ NEWS
CLASS ACTION CASE DETAILS: The filed complaint alleges that Frequency Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: the Company's Phase 2a trial results failed to live up to the Company's expectations as the results revealed no discernable difference between FX-322 and the placebo. In spite of the disappointing results, the Company continued to conduct the Phase 2a study while releasing positive statements in earnings calls, press releases, SEC filings, and pharmaceutical presentations about FX-322's potential. These statements materially misled the market and artificially inflated the value of Frequency's common stock.
WHAT THIS MEANS TO YOU AS A SHAREHOLDER: If you have suffered a loss in Frequency Therapeutics you have until August 2, 2021 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NO COST TO YOU: If you purchased Frequency Therapeutics securities during the relevant period, you may be entitled to compensation without payment of any out-of-pocket fees.
ABOUT KLEIN LAW FIRM
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. The Klein Law Firm is a boutique litigation firm with experience in a wide range of areas including securities law, corporate finance and commercial litigation. Since 2011, our experienced attorneys have achieved superior results for our clients with a personalized focus. Attorney advertising. Prior results do not guarantee similar outcomes.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/88526